TIR domain-containing adapter molecule 1

Gavin AL et al. (2006) Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling.

Zhang Q et al. (2020) Inborn errors of type I IFN immunity in patients with life-threatening COVID-19.

Meylan E et al. (2004) RIP1 is an essential mediator of Toll-like receptor 3-induced NF-kappa B activation.

Mørk N et al. (2015) Mutations in the TLR3 signaling pathway and beyond in adult patients with herpes simplex encephalitis.

Liu S et al. (2015) Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation.

Rathinam VA et al. (2012) TRIF licenses caspase-11-dependent NLRP3 inflammasome activation by gram-negative bacteria.

Yamamoto M et al. (2002) Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling.

Oshiumi H et al. (2003) TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction.

Yamamoto M et al. (2003) Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway.

Hoebe K et al. (2003) Identification of Lps2 as a key transducer of MyD88-independent TIR signalling.

Carty M et al. (2006) The human adaptor SARM negatively regulates adaptor protein TRIF-dependent Toll-like receptor signaling.

Riad A et al. (2011) TRIF is a critical survival factor in viral cardiomyopathy.

Zhang Z et al. (2011) DDX1, DDX21, and DHX36 helicases form a complex with the adaptor molecule TRIF to sense dsRNA in dendritic cells.

Sancho-Shimizu V et al. (2011) Herpes simplex encephalitis in children with autosomal recessive and dominant TRIF deficiency.